Cargando…

Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study

BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Jin, Lee, Oh Young, Lee, Kang Nyeong, Lee, Sung Joon, Jang, Jae-Young, Cho, Jin Woong, Kim, Tae-Oh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Neurogastroenterology and Motility 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657924/
https://www.ncbi.nlm.nih.gov/pubmed/31327222
http://dx.doi.org/10.5056/jnm18185
_version_ 1783438874115047424
author Kim, Eun Jin
Lee, Oh Young
Lee, Kang Nyeong
Lee, Sung Joon
Jang, Jae-Young
Cho, Jin Woong
Kim, Tae-Oh
author_facet Kim, Eun Jin
Lee, Oh Young
Lee, Kang Nyeong
Lee, Sung Joon
Jang, Jae-Young
Cho, Jin Woong
Kim, Tae-Oh
author_sort Kim, Eun Jin
collection PubMed
description BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effective and safe in treating NERD. The aim of the study is to evaluate the efficacy and safety of AlbisD compared with omperazole in patients with NERD. METHODS: This was a multicenter, randomized, open-label, parallel-group, non-inferiority comparative study. A total of 126 patients with NERD were randomly allocated to either AlbisD twice daily or omeprazole 20 mg once daily for 4 weeks from February 2016 to August 2016. The study patients had histories of heartburn or regurgitation of moderate severity (> score 2) and a frequency of at least 2 episodes per week, and had no mucosal breaks of the esophagus on endoscopy. The primary efficacy variable was complete cure of heartburn at week 4. Secondary efficacy variables evaluating symptoms of heartburn and acid reflux as well as safety profiles were compared in the 2 groups at week 2 and 4 after treatment. RESULTS: A total of 113 patients completed the study (57 and 56 in AlbisD and omeprazole groups, respectively). The proportion of patients with complete cure of heartburn at week 4 was not significantly different between the AlbisD and omeprazole groups (35.1% vs 32.1% respectively, P = 0.740). There were no significant differences between the 2 groups in the any secondary variables including proportions of days without heartburn or acid reflux over 4 weeks (including daytime and nighttime). Adverse events were similarly reported in the 2 groups (7 [12.3%] vs 6 [10.7%]), and there were no serious adverse events. CONCLUSIONS: The efficacy and safety of AlibsD in treating NERD patients are not inferior to those of omeprazole. Therefore, AlbisD can be an alternative to PPIs for NERD.
format Online
Article
Text
id pubmed-6657924
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-66579242019-07-31 Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study Kim, Eun Jin Lee, Oh Young Lee, Kang Nyeong Lee, Sung Joon Jang, Jae-Young Cho, Jin Woong Kim, Tae-Oh J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effective and safe in treating NERD. The aim of the study is to evaluate the efficacy and safety of AlbisD compared with omperazole in patients with NERD. METHODS: This was a multicenter, randomized, open-label, parallel-group, non-inferiority comparative study. A total of 126 patients with NERD were randomly allocated to either AlbisD twice daily or omeprazole 20 mg once daily for 4 weeks from February 2016 to August 2016. The study patients had histories of heartburn or regurgitation of moderate severity (> score 2) and a frequency of at least 2 episodes per week, and had no mucosal breaks of the esophagus on endoscopy. The primary efficacy variable was complete cure of heartburn at week 4. Secondary efficacy variables evaluating symptoms of heartburn and acid reflux as well as safety profiles were compared in the 2 groups at week 2 and 4 after treatment. RESULTS: A total of 113 patients completed the study (57 and 56 in AlbisD and omeprazole groups, respectively). The proportion of patients with complete cure of heartburn at week 4 was not significantly different between the AlbisD and omeprazole groups (35.1% vs 32.1% respectively, P = 0.740). There were no significant differences between the 2 groups in the any secondary variables including proportions of days without heartburn or acid reflux over 4 weeks (including daytime and nighttime). Adverse events were similarly reported in the 2 groups (7 [12.3%] vs 6 [10.7%]), and there were no serious adverse events. CONCLUSIONS: The efficacy and safety of AlibsD in treating NERD patients are not inferior to those of omeprazole. Therefore, AlbisD can be an alternative to PPIs for NERD. Korean Society of Neurogastroenterology and Motility 2019-07 2019-07-30 /pmc/articles/PMC6657924/ /pubmed/31327222 http://dx.doi.org/10.5056/jnm18185 Text en © 2019 The Korean Society of Neurogastroenterology and Motility This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Eun Jin
Lee, Oh Young
Lee, Kang Nyeong
Lee, Sung Joon
Jang, Jae-Young
Cho, Jin Woong
Kim, Tae-Oh
Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
title Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
title_full Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
title_fullStr Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
title_full_unstemmed Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
title_short Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
title_sort efficacy and safety of albisd compared with omeprazole 20 mg in patients with non-erosive reflux disease: a randomized, open-label, active-controlled, pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657924/
https://www.ncbi.nlm.nih.gov/pubmed/31327222
http://dx.doi.org/10.5056/jnm18185
work_keys_str_mv AT kimeunjin efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy
AT leeohyoung efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy
AT leekangnyeong efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy
AT leesungjoon efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy
AT jangjaeyoung efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy
AT chojinwoong efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy
AT kimtaeoh efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy